Last reviewed · How we verify

Horizontal forehead lines — Treatment Landscape & Competitive Intelligence

Horizontal forehead lines (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Horizontal forehead lines, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Xeomin INCOBOTULINUMTOXINA Merz Pharms Acetylcholine Release Inhibitor [EPC] 2015-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Merz Pharms · 1 drug in Horizontal forehead lines

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Horizontal forehead lines:

Cite this brief

Drug Landscape (2026). Horizontal forehead lines — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/horizontal-forehead-lines. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing